Rapport Therapeutics (RAPP) Amortizatization of Intangibles (2023 - 2026)
Rapport Therapeutics (RAPP) reported Amortizatization of Intangibles of $364000.0 for Q1 2026, down 11.44% year-over-year from $411000.0 in Q1 2025, and down 66.04% quarter-over-quarter from $1.1 million in Q4 2025.
Rapport Therapeutics (RAPP) Amortizatization of Intangibles (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has 4 years of Amortizatization of Intangibles data on file, last reported at $364000.0 in Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $364000.0, down 11.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (up 50.39% YoY), and the FY2025 annual result was $1.4 million, up 117.45% from the prior year.
- Amortizatization of Intangibles retreated to $364000.0 in Q1 2026 per RAPP's latest filing, from $1.1 million in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $1.7 million in Q2 2024 and troughed at -$1.3 million in Q3 2024.
- A 4-year average of $242500.0 and a median of $160500.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2024 and 2025: Amortizatization of Intangibles jumped 617.39% in 2024, then slumped 92.91% in 2025.
- A 4-year view of Amortizatization of Intangibles shows it stood at $23000.0 in 2023, then jumped by 617.39% to $165000.0 in 2024, then jumped by 549.7% to $1.1 million in 2025, then tumbled by 66.04% to $364000.0 in 2026.
- Business Quant data shows RAPP's Amortizatization of Intangibles at $364000.0 in Q1 2026, $1.1 million in Q4 2025, and -$204000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Rapport Therapeutics | 1.66 Bn | 1.66 Bn | - | 364,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 364,000.00 |
| Mar 31, 2026 | 364,000.00 |
| Dec 31, 2025 | 1.07 Mn |
| Dec 31, 2025 | 1.07 Mn |
| Sep 30, 2025 | -204,000.00 |
| Sep 30, 2025 | -204,000.00 |
| Jun 30, 2025 | 117,000.00 |
| Jun 30, 2025 | 117,000.00 |
| Mar 31, 2025 | 411,000.00 |
| Mar 31, 2025 | 411,000.00 |
| Dec 31, 2024 | 165,000.00 |
| Dec 31, 2024 | 165,000.00 |
| Sep 30, 2024 | -1.33 Mn |
| Sep 30, 2024 | -1.33 Mn |
| Jun 30, 2024 | 1.65 Mn |
| Jun 30, 2024 | 1.65 Mn |
| Mar 31, 2024 | 156,000.00 |
| Mar 31, 2024 | 156,000.00 |
| Dec 31, 2023 | 23,000.00 |
| Dec 31, 2023 | 23,000.00 |